Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans.
about
Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality?Mitigating permeability-mediated risks in drug discovery.Predictive tools for the evaluation of microbial effects on drugs during gastrointestinal passage.Modeling bioavailability to organs protected by biological barriers.Requirements for the formal representation of pathophysiology mechanisms by cliniciansIntestinal solubility and absorption of poorly water soluble compounds: predictions, challenges and solutions.Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.The fraction dose absorbed, in humans, and high jejunal human permeability relationship.Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preferenceWarfarin bioavailability with feeding tubes and enteral formula.Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human.Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.In Silico ADME/Tox PredictionsADME
P2860
Q26765790-B1A21774-F472-4F3A-A362-F0A9C72EC609Q37671826-EE880D2D-A5FC-4E1D-B6E3-AD86EE76DD08Q37724176-8583DA04-B679-4B41-B2CD-212F2B208F9BQ38288015-E24FDF3C-60B8-495D-A467-CC4362AB59D6Q38558422-D663E959-9E98-486C-9EFF-B64E267DDF27Q38575611-0FE67308-7432-4DA3-8167-321E1352AB6DQ39548977-ADB89A3D-CFB8-433F-9EE1-E0500D98F97FQ42131253-FA253C99-9620-46BD-8D8A-D5E4B22904B4Q42642958-AAD7BF78-9580-42A4-A7D2-724DD343F2BCQ43064102-9B5B992E-F704-494E-B064-A049128FB08FQ46977325-B1F3D563-D541-487E-AAB3-948A2CE5AACEQ50634271-15BA4717-ECB6-4DF7-8DF7-5AD14BA623A2Q50871327-98872884-CF62-4A15-B4B8-20957DC42D12Q56984194-5FF7C75A-7C9E-4582-BF5C-DEBD789558E2Q57684720-87DC3837-1131-4700-97E6-922E6C989ABF
P2860
Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Modeling gastrointestinal drug ...... ermeability studies in humans.
@ast
Modeling gastrointestinal drug ...... ermeability studies in humans.
@en
Modeling gastrointestinal drug ...... ermeability studies in humans.
@nl
type
label
Modeling gastrointestinal drug ...... ermeability studies in humans.
@ast
Modeling gastrointestinal drug ...... ermeability studies in humans.
@en
Modeling gastrointestinal drug ...... ermeability studies in humans.
@nl
prefLabel
Modeling gastrointestinal drug ...... ermeability studies in humans.
@ast
Modeling gastrointestinal drug ...... ermeability studies in humans.
@en
Modeling gastrointestinal drug ...... ermeability studies in humans.
@nl
P1476
Modeling gastrointestinal drug ...... ermeability studies in humans.
@en
P2093
Hans Lennernäs
P304
P356
10.2174/138920007782109823
P407
P577
2007-10-01T00:00:00Z